Filing Flows › Comparisons › MRMD vs NAGE
Marimed vs Niagen Bioscience: MRMD and NAGE compared
Marimed is the larger company: $41.9M of revenue in its latest quarter (Q2 2026) against $27.2M for Niagen Bioscience (Q3 2026). Marimed is growing faster (+6% against -20% a year earlier). Marimed is more profitable, with an operating margin of 1.0% against -5.8%.
Where the money goes: MRMD and NAGE
Marimed (MRMD) · Q2 2026
Marimed, Q2 2026: revenue $41.9M (+6% year over year), operating margin 1.0%, net loss $3.6M, operating cash flow $2.2M. The chart follows the revenue to costs, profit and cash.
Niagen Bioscience (NAGE) · Q3 2026
Niagen Bioscience, Q3 2026: revenue $27.2M (-20% year over year), operating margin -5.8%, net loss $1.2M, operating cash flow $2.6M. The chart follows the revenue to costs, profit and cash.
| Marimed (MRMD) | Niagen Bioscience (NAGE) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $41.9M | $27.2M |
| Revenue growth, Y/Y | +6% | -20% |
| Operating margin | 1.0% | -5.8% |
| Net earnings | −$3.6M | −$1.2M |
| Net margin | -8.5% | -4.3% |
| Operating cash flow | $2.2M | $2.6M |
| Free cash flow | $1.9M | — |
Where the revenue comes from
Marimed
- Product sales - retail: $23.2M (55%)
- Product sales - wholesale: $18.5M (44%)
- Other revenue: $193K (0%)
Niagen Bioscience
- Consumer Products segment: $23.3M (86%)
- Ingredients segment: $3.8M (14%)
Questions
Which is bigger, Marimed or Niagen Bioscience?
Marimed is the larger company: $41.9M of revenue in its latest quarter (Q2 2026) against $27.2M for Niagen Bioscience (Q3 2026).
Is Marimed or Niagen Bioscience growing faster?
Marimed is growing faster (+6% against -20% a year earlier).
Which is more profitable, Marimed or Niagen Bioscience?
Marimed is more profitable, with an operating margin of 1.0% against -5.8%.
More: Marimed earnings · how Marimed makes money · Niagen Bioscience earnings · how Niagen Bioscience makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.